-
Je něco špatně v tomto záznamu ?
Bioavailability Enhancement and Food Effect Elimination of Abiraterone Acetate by Encapsulation in Surfactant-Enriched Oil Marbles
T. Boleslavská, O. Rychecký, M. Krov, P. Žvátora, O. Dammer, J. Beránek, P. Kozlík, T. Křížek, J. Hořínková, P. Ryšánek, J. Roušarová, NK. Canová, M. Šíma, O. Slanař, F. Štěpánek
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- abirateron aplikace a dávkování chemie farmakokinetika MeSH
- aplikace orální MeSH
- biologická dostupnost MeSH
- farmaceutická vehikula chemie MeSH
- interakce mezi potravou a léky MeSH
- krysa rodu rattus MeSH
- modely u zvířat MeSH
- oleje chemie MeSH
- omezení příjmu potravy fyziologie MeSH
- plocha pod křivkou MeSH
- postprandiální období fyziologie MeSH
- povrchově aktivní látky chemie MeSH
- příprava léků metody MeSH
- uvolňování léčiv MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Abiraterone acetate has limited bioavailability in the fasted state and exhibits a strong positive food effect. We present a novel formulation concept based on the so-called oil marbles (OMs) and show by in vitro and in vivo experiments that the food effect can be suppressed. OMs are spherical particles with a core-shell structure, formed by coating oil-based droplets that contain the dissolved drug by a layer of powder that prevents the cores from sticking and coalescence. OMs prepared in this work contained abiraterone acetate in the amorphous form and showed enhanced dissolution properties during in vitro experiments when compared with originally marketed formulation of abiraterone acetate (Zytiga®). Based on in vitro comparison of OMs containing different oil/surfactant combinations, the most promising formulation was chosen for in vivo studies. To ensure relevance, it was verified that the food effect previously reported for Zytiga® in humans was translated into the rat animal model. The bioavailability of abiraterone acetate formulated in OMs in the fasted state was then found to be enhanced by a factor of 2.7 in terms of AUC and by a factor of 4.0 in terms of Cmax. Crucially, the food effect reported in the literature for other abiraterone acetate formulations was successfully eliminated and OMs showed comparable extent of bioavailability in a fed-fasted study. Oil marbles therefore seem to be a promising formulation concept not only for abiraterone acetate but potentially also for other poorly soluble drugs that reveal a positive food effect.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026550
- 003
- CZ-PrNML
- 005
- 20230703085900.0
- 007
- ta
- 008
- 211013s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1208/s12248-020-00505-5 $2 doi
- 035 __
- $a (PubMed)32978690
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Boleslavská, Tereza $u Zentiva, k.s., U Kabelovny 130, 102 37, Prague, Czech Republic $u Department of Chemical Engineering, University of Chemistry and Technology, Prague, Technická 5, 166 28, Prague, Czech Republic
- 245 10
- $a Bioavailability Enhancement and Food Effect Elimination of Abiraterone Acetate by Encapsulation in Surfactant-Enriched Oil Marbles / $c T. Boleslavská, O. Rychecký, M. Krov, P. Žvátora, O. Dammer, J. Beránek, P. Kozlík, T. Křížek, J. Hořínková, P. Ryšánek, J. Roušarová, NK. Canová, M. Šíma, O. Slanař, F. Štěpánek
- 520 9_
- $a Abiraterone acetate has limited bioavailability in the fasted state and exhibits a strong positive food effect. We present a novel formulation concept based on the so-called oil marbles (OMs) and show by in vitro and in vivo experiments that the food effect can be suppressed. OMs are spherical particles with a core-shell structure, formed by coating oil-based droplets that contain the dissolved drug by a layer of powder that prevents the cores from sticking and coalescence. OMs prepared in this work contained abiraterone acetate in the amorphous form and showed enhanced dissolution properties during in vitro experiments when compared with originally marketed formulation of abiraterone acetate (Zytiga®). Based on in vitro comparison of OMs containing different oil/surfactant combinations, the most promising formulation was chosen for in vivo studies. To ensure relevance, it was verified that the food effect previously reported for Zytiga® in humans was translated into the rat animal model. The bioavailability of abiraterone acetate formulated in OMs in the fasted state was then found to be enhanced by a factor of 2.7 in terms of AUC and by a factor of 4.0 in terms of Cmax. Crucially, the food effect reported in the literature for other abiraterone acetate formulations was successfully eliminated and OMs showed comparable extent of bioavailability in a fed-fasted study. Oil marbles therefore seem to be a promising formulation concept not only for abiraterone acetate but potentially also for other poorly soluble drugs that reveal a positive food effect.
- 650 _2
- $a abirateron $x aplikace a dávkování $x chemie $x farmakokinetika $7 D000069501
- 650 _2
- $a aplikace orální $7 D000284
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a plocha pod křivkou $7 D019540
- 650 _2
- $a biologická dostupnost $7 D001682
- 650 _2
- $a příprava léků $x metody $7 D004339
- 650 _2
- $a uvolňování léčiv $7 D065546
- 650 _2
- $a omezení příjmu potravy $x fyziologie $7 D005215
- 650 _2
- $a interakce mezi potravou a léky $7 D018565
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a modely u zvířat $7 D023421
- 650 _2
- $a oleje $x chemie $7 D009821
- 650 _2
- $a farmaceutická vehikula $x chemie $7 D014677
- 650 _2
- $a postprandiální období $x fyziologie $7 D019518
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a povrchově aktivní látky $x chemie $7 D013501
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Rychecký, Ondřej $u Zentiva, k.s., U Kabelovny 130, 102 37, Prague, Czech Republic $u Department of Chemical Engineering, University of Chemistry and Technology, Prague, Technická 5, 166 28, Prague, Czech Republic
- 700 1_
- $a Krov, Martin $u Department of Chemical Engineering, University of Chemistry and Technology, Prague, Technická 5, 166 28, Prague, Czech Republic
- 700 1_
- $a Žvátora, Pavel $u Zentiva, k.s., U Kabelovny 130, 102 37, Prague, Czech Republic
- 700 1_
- $a Dammer, Ondřej $u Zentiva, k.s., U Kabelovny 130, 102 37, Prague, Czech Republic $7 xx0303489
- 700 1_
- $a Beránek, Josef $u Zentiva, k.s., U Kabelovny 130, 102 37, Prague, Czech Republic
- 700 1_
- $a Kozlík, Petr $u Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic
- 700 1_
- $a Křížek, Tomáš $u Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic
- 700 1_
- $a Hořínková, Jana $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Ryšánek, Pavel $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Roušarová, Jaroslava $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $7 xx0268379
- 700 1_
- $a Canová, Nikolina Kutinová $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Šíma, Martin $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Slanař, Ondřej $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Štěpánek, František $u Department of Chemical Engineering, University of Chemistry and Technology, Prague, Technická 5, 166 28, Prague, Czech Republic. Frantisek.Stepanek@vscht.cz
- 773 0_
- $w MED00163142 $t The AAPS journal $x 1550-7416 $g Roč. 22, č. 6 (2020), s. 122
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32978690 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20230703085858 $b ABA008
- 999 __
- $a ok $b bmc $g 1715316 $s 1147057
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 22 $c 6 $d 122 $e 20200925 $i 1550-7416 $m The AAPS journal $n AAPS J $x MED00163142
- LZP __
- $a Pubmed-20211013